Skip to main content
SpringerLink
Log in

Methadone and Buprenorphine: The Place of Opiate Replacement Therapies

  • Chapter
  • First Online:
Treating Comorbid Opioid Use Disorder in Chronic Pain

Abstract

Pharmacotherapy is the mainstay and standard of care for treatment of opioid use disorder with behavioral interventions serving as essential adjunctive treatment. Managing patients with opioid use disorder without medications typically fails with 80–90 % relapse rates described (Ball and Ross. The effectiveness of methadone maintenance treatment: clients, programs, services, and outcome. New York: Springer; 1991; Weiss et al. Arch Gen Psychiatry. 2011;68(12):1238–46). Methadone, a full μ-opioid agonist, and buprenorphine, a μ-opioid partial agonist and κ-opioid antagonist, are two FDA-approved medications for the treatment of opioid use disorder. In this chapter, we will discuss the role of these medications in the treatment of opioid use disorder while describing what data exist on the role of these medications in treatment of patients with co-occurring chronic pain and opioid use disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Saxon AJ. Treatment of opioid dependence. In: Ko M-C, Husbands SM, editors. Research and development of opioid-related ligands. New York: Oxford University Press; 2013. p. 61–102.

    Chapter  Google Scholar 

  2. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50(6):551–9.

    Article  CAS  PubMed  Google Scholar 

  3. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.

    Article  CAS  PubMed  Google Scholar 

  4. Armstrong SC, Cozza KL. Med-psych drug-drug interaction update. Psychosomatics. 2001;42(5):435–7.

    Article  CAS  PubMed  Google Scholar 

  5. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Mange. 2002;23(2):148–53.

    Article  Google Scholar 

  6. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Strain EC, Bigelow GE, Lievson IA, Stilzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281(11):100–5.

    Article  Google Scholar 

  8. Abuse S, Administration MHS. Managing chronic pain in adults with or in recovery from substance use disorders. HHS publication No. (SMA) 12-4671, Treatment improvement protocol (TIP), vol. 54. Rockville: Substance Abuse and Mental Health Services Administration; 2011.

    Google Scholar 

  9. Eyler E. Chronic and acute pain and pain management for patients in methadone maintenance treatment. Am J Addict. 2013;22:75–83.

    Article  PubMed  Google Scholar 

  10. Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med. 2014;15(9):1540–8.

    Article  PubMed  Google Scholar 

  11. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction. J Addict Dis. 2013;32(1):68–78.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Blinderman CD, Sekine R, Zhang B, et al. Methadone as an analgesic for patients with chronic pain in methadone maintenance treatment programs (MMTPs). J Opioid Manag. 2009;5:107–14.

    PubMed  Google Scholar 

  13. Angst MS, Clark DJ. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–87.

    Article  CAS  PubMed  Google Scholar 

  14. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213–7.

    Article  CAS  PubMed  Google Scholar 

  15. Clark MR, Stoller KB, Brooner RK. Assessment and management of chronic pain in individuals seeking treatment for opioid use disorder. Can J Psychiatry. 2008;53(8):496–508.

    PubMed  Google Scholar 

  16. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005.

    Google Scholar 

  17. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effect at high doses. Clin Pharmacol Ther. 1994;55(5):569–80.

    Article  CAS  PubMed  Google Scholar 

  18. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39–47.

    Article  CAS  PubMed  Google Scholar 

  19. Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol. 1999;39(6):619–23.

    Article  CAS  PubMed  Google Scholar 

  20. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, et al. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets. 2007;8(1):117–35.

    Article  CAS  PubMed  Google Scholar 

  21. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohl Depend. 2003;70(2 Suppl):S13–27.

    Article  CAS  Google Scholar 

  22. Debelak K, Korrone WR, O’Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. Am J Addict. 2013;22(3):252–4.

    Article  PubMed  Google Scholar 

  23. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6(3):249–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in burprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2-3):326–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sanson RA, Sansone LA. Buprenorphine treatment for narcotic addiction: not without risks. Innov Clin Neurosci. 2015;12(3-4):32–6.

    Google Scholar 

  26. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1-2):71–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253–9.

    Article  PubMed  Google Scholar 

  28. Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi Jr J. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 suppl):ES59–66.

    PubMed  Google Scholar 

  29. Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain. 2008;24(2):93–7.

    Article  PubMed  Google Scholar 

  30. Malinoff HL, Barkin RL, et al. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):410–8.

    Article  Google Scholar 

  31. Chen K, Chen L, Mao J. Buprenorphine-Naloxone therapy in pain management. Anesthesiology. 2014;120:1262–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pade PA, Cardon KE, et al. Prescription opioid abuse, chronic pain, and primary care: a co-occurring disorders clinic in the chronic disease model. J Subst Abuse Treat. 2012;43:446–50.

    Article  PubMed  Google Scholar 

  33. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150–68.

    Article  CAS  PubMed  Google Scholar 

  34. Gourlay DL, Heit HA. Pain and addiction: managing risk through comprehensive care. J Addict Dis. 2008;27(3):23–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VA Puget Sound Health Care System (S-116 ATC), 1660 S. Columbian Way, Seattle, WA, 98108, USA

    Jonathan R. Buchholz M.D. & Andrew J. Saxon M.D.

  2. Department of Psychiatry & Behavioral Sciences, University of Washington, 1660 S. Columbian Way, Seattle, WA, 98108, USA

    Jonathan R. Buchholz M.D. & Andrew J. Saxon M.D.

Authors
  1. Jonathan R. Buchholz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Saxon M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan R. Buchholz M.D. .

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Department of Psychiatry, Portland, Oregon, USA

    Annette M. Matthews

  2. Maine Medical Center, Department of Psychiatry, Portland, Oregon, USA

    Jonathan C. Fellers

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Buchholz, J.R., Saxon, A.J. (2016). Methadone and Buprenorphine: The Place of Opiate Replacement Therapies. In: Matthews, A., Fellers, J. (eds) Treating Comorbid Opioid Use Disorder in Chronic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-29863-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29863-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29861-0

  • Online ISBN: 978-3-319-29863-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation